In less than three months since U.S. Senator Tammy Baldwin and her congressional colleagues initiated an investigation into the practices of major American inhaler manufacturers, significant progress has been made. Three out of the four companies under scrutiny have acquiesced to demands, pledging to cap the costs of inhalers at $35 for patients who currently face substantially higher expenses.
The significance of this action cannot be overstated, considering that approximately 25 million Americans suffer from asthma and 16 million from chronic obstructive pulmonary disease (COPD), constituting a combined total of over 40 million individuals reliant on inhalers for essential respiratory support.
Despite being a staple in respiratory treatment since the 1950s, inhalers continue to be marked by exorbitant costs, particularly in the United States. Many of the medications contained within these devices have been on the market for over a quarter of a century.
According to statements from Senator Baldwin’s office, inhaler manufacturers sell identical products at significantly reduced rates in other nations. For instance, AstraZeneca’s Breztri Aerosphere inhaler is priced at $645 in the U.S., yet only $49 in the UK. Similar disparities exist for inhalers produced by Boehringer Ingelheim, GlaxoSmithKline, and Teva.
Senator Baldwin, alongside Democratic colleagues such as Senators Ben Ray Luján, Ed Markey, and Bernie Sanders, exerted pressure on these companies through a series of inquiries and correspondence. They demanded transparency, requesting documents that elucidate the reasons behind the stark pricing contrasts between the United States and Europe.
In her capacity as the ranking member of the Senate Committee on Health, Education, Labor, and Pensions, Senator Baldwin recently announced a breakthrough. As a direct result of the letters sent to the manufacturers, commitments have been secured from three of the four companies to reduce the out-of-pocket expenses for inhalers to a fixed rate of $35.00. This move signifies a significant step forward in ensuring affordable access to essential respiratory medication for millions of Americans.
“For the millions of Americans who rely on inhalers to breathe, this news is a major step in the right direction as we work to lower costs and hold big drug companies accountable,” said Senator Baldwin.
A full list of the inhalers and associated drugs is now available online.
For the second time within the span of a year, pharmaceutical companies have been compelled to offer medications at more accessible prices. This latest development follows a successful initiative, spearheaded by the White House and supported by Congressional actions, which resulted in the capping of insulin costs at $35 per month. This marks another significant stride in the ongoing efforts to ensure affordability and accessibility in healthcare, particularly concerning crucial medications like insulin.
Recommended For You
